Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec ...
... target to $20 (from $15), following the company's preclinical study results of PEGPH20 in combination with cancer immunotherapy in solid cancers.
Personalized Immunotherapy for Advanced Non-Small Cell Lung Cancer. Wednesday, February 18, 2015 10:30 am - 11:30 am, Neuroscience ...
The development of treatments for pancreatic cancer is extremely tough and challenging. Incentives that come with orphan drug status include tax ...
And while it isn't untrue—there is evidence dogs can smell cancer—the ... for deadlier and more hidden forms of the disease, like pancreatic cancer.
... with Abraxane and Gemzar, compared to Abraxane plus Gemzar alone for the treatment of metastatic pancreatic cancer. Data from the study should ...
Teaching T cells to hunt cancer has spurred remissions in two kinds of ... a range of tests to determine a target for the immune system in glioblastoma.
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. CEL-SCI believes that the ...
We want to find out if we may be able to utilize this 'window of opportunity' to rev up the immune system and keep metastatic cancer at bay.”.
The getting has two crucial implications for sufferers with bladder cancer. Initially, by assessing levels of TERT mRNA (which far more straight ...
Findings may help doctors recommend appropriate treatments, improve patient outcomes - News-Medical.net
Heat has no products on the market but is developing drugs for bladder cancer and lung cancer. The company expects to report initial results from a ...
Heat Biologics, Inc. and OncoSec Medical Inc. Announce Collaboration to Evaluate Combination of ... -GlobeNewswire (press release)
Trial Confirms RT Survival Benefit With ADT in Prostate Cancer
An 8-year analysis confirmed that adding radiotherapy to androgen deprivation therapy in prostate cancer improved patient overall survival by more than a year.
An 8-year analysis confirmed that adding radiotherapy to androgen deprivation therapy in prostate cancer improved patient overall survival by more than a year.
CDH1 Mutations Bring High Gastric Cancer Risk
According to a large study, men with a CDH1 gene mutation have a 70% incidence of gastric cancer by the age of 80 years and women have a 56% incidence.
According to a large study, men with a CDH1 gene mutation have a 70% incidence of gastric cancer by the age of 80 years and women have a 56% incidence.
Tarextumab Gets FDA Orphan Drug Designation for Lung, Pancreatic Cancer
The US Food and Drug Administration has granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and small-cell lung cancer.
The US Food and Drug Administration has granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and small-cell lung cancer.
RCC Drug Axitinib Could Treat TKI-Resistant CML
Researchers have shown that axitinib could be repurposed as a treatment for CML patients resistant to standard TKIs through a certain molecular mechanism.
Researchers have shown that axitinib could be repurposed as a treatment for CML patients resistant to standard TKIs through a certain molecular mechanism.
Large Meta-Analysis Links Hormone Therapy With Ovarian Cancer Risk
A large meta-analysis found that women who were users of hormone therapy, even those with less than 5 years of use, had an increased risk of ovarian cancer.
A large meta-analysis found that women who were users of hormone therapy, even those with less than 5 years of use, had an increased risk of ovarian cancer.
Long-Term QOL Decline Seen in Some Low-Grade Glioma Survivors
Stable, long-term survivors of low-grade glioma were able to maintain a high level of quality of life, but did experience detectable declines in certain areas.
Stable, long-term survivors of low-grade glioma were able to maintain a high level of quality of life, but did experience detectable declines in certain areas.
Omacetaxine Effective for Intolerant/Resistant CML
In two phase II trials, the protein synthesis inhibitor omacetaxine offered long-term efficacy in some patients with chronic-phase and accelerated-phase CML.
In two phase II trials, the protein synthesis inhibitor omacetaxine offered long-term efficacy in some patients with chronic-phase and accelerated-phase CML.
Science Daily Cancer News
A tool for keeping the most common forms of cancer at bay could be in your gut, a new study concludes. For the study, the research team tested thousands of chemicals found in the body with the help of a robot and discovered more than 20 that could delay the aging process, something inevitably linked to cancer.
Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, a study concludes.
Levels of mRNA for the gene TERT predict patient outcomes in bladder cancer, scientists have discovered. Results may help doctors and researchers mark especially aggressive bladder cancers, allowing them to recommend appropriate treatments and improve patient outcomes.
A researcher brings a paleontological view of species extinction to bear on the challenges involved in driving populations of cancer cells to annihilation -- or at least improving patient prognosis through disease-limiting efforts.
New research reveals a high value of scans which could lead to future change of reimbursement policies for follow-up positron emission tomography/computed tomography studies in lung cancer. The study establishes the value of fourth and subsequent follow-up PET/CT scans in clinical assessment and management change in patients with the disease.
The topical medicine pimecrolimus to treat eczema (atopic dermatitis or AD) in children appears unlikely to be associated with increased of risk of cancer based on how it was used in group of children followed for 10 years, according to an article.
A study suggests a new way to trace cancer back to its cell type of origin, providing new insights into the early events that shape a cancer, and could have important implications for the many cancer patients for whom the originating site of the cancer is unknown.
For the first time scientists show the importance of DNA damage in fine tuning of our innate immune system and hence the ability to mount the optimal inflammatory response to infections and other biological dangers.
Tambahkan Komentar